S&P 500   4,291.03 (+0.20%)
DOW   33,764.31 (+0.00%)
QQQ   356.11 (+0.41%)
AAPL   183.77 (+1.56%)
MSFT   336.40 (+0.30%)
META   271.50 (-0.41%)
GOOGL   126.07 (+1.12%)
AMZN   124.27 (+0.02%)
TSLA   220.74 (+3.16%)
NVDA   394.50 (+0.31%)
NIO   7.73 (+2.25%)
BABA   83.86 (-0.49%)
AMD   118.34 (+0.41%)
T   15.32 (+0.72%)
F   12.60 (+1.69%)
MU   68.81 (-0.52%)
CGC   0.82 (-0.62%)
GE   105.08 (-0.68%)
DIS   90.50 (-0.30%)
AMC   4.64 (+1.98%)
PFE   38.52 (+0.42%)
PYPL   64.37 (+0.64%)
NFLX   404.29 (+0.95%)
S&P 500   4,291.03 (+0.20%)
DOW   33,764.31 (+0.00%)
QQQ   356.11 (+0.41%)
AAPL   183.77 (+1.56%)
MSFT   336.40 (+0.30%)
META   271.50 (-0.41%)
GOOGL   126.07 (+1.12%)
AMZN   124.27 (+0.02%)
TSLA   220.74 (+3.16%)
NVDA   394.50 (+0.31%)
NIO   7.73 (+2.25%)
BABA   83.86 (-0.49%)
AMD   118.34 (+0.41%)
T   15.32 (+0.72%)
F   12.60 (+1.69%)
MU   68.81 (-0.52%)
CGC   0.82 (-0.62%)
GE   105.08 (-0.68%)
DIS   90.50 (-0.30%)
AMC   4.64 (+1.98%)
PFE   38.52 (+0.42%)
PYPL   64.37 (+0.64%)
NFLX   404.29 (+0.95%)
S&P 500   4,291.03 (+0.20%)
DOW   33,764.31 (+0.00%)
QQQ   356.11 (+0.41%)
AAPL   183.77 (+1.56%)
MSFT   336.40 (+0.30%)
META   271.50 (-0.41%)
GOOGL   126.07 (+1.12%)
AMZN   124.27 (+0.02%)
TSLA   220.74 (+3.16%)
NVDA   394.50 (+0.31%)
NIO   7.73 (+2.25%)
BABA   83.86 (-0.49%)
AMD   118.34 (+0.41%)
T   15.32 (+0.72%)
F   12.60 (+1.69%)
MU   68.81 (-0.52%)
CGC   0.82 (-0.62%)
GE   105.08 (-0.68%)
DIS   90.50 (-0.30%)
AMC   4.64 (+1.98%)
PFE   38.52 (+0.42%)
PYPL   64.37 (+0.64%)
NFLX   404.29 (+0.95%)
S&P 500   4,291.03 (+0.20%)
DOW   33,764.31 (+0.00%)
QQQ   356.11 (+0.41%)
AAPL   183.77 (+1.56%)
MSFT   336.40 (+0.30%)
META   271.50 (-0.41%)
GOOGL   126.07 (+1.12%)
AMZN   124.27 (+0.02%)
TSLA   220.74 (+3.16%)
NVDA   394.50 (+0.31%)
NIO   7.73 (+2.25%)
BABA   83.86 (-0.49%)
AMD   118.34 (+0.41%)
T   15.32 (+0.72%)
F   12.60 (+1.69%)
MU   68.81 (-0.52%)
CGC   0.82 (-0.62%)
GE   105.08 (-0.68%)
DIS   90.50 (-0.30%)
AMC   4.64 (+1.98%)
PFE   38.52 (+0.42%)
PYPL   64.37 (+0.64%)
NFLX   404.29 (+0.95%)
NYSEAMERICAN:SYN

Synthetic Biologics (SYN) Stock Forecast, Price & News

$1.02
+0.01 (+0.99%)
(As of 10/12/2022)
Compare
Today's Range
$0.97
▼
$1.02
50-Day Range
N/A
52-Week Range
$0.97
▼
$4.56
Volume
57,700 shs
Average Volume
197,338 shs
Market Capitalization
$16.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

SYN stock logo

About Synthetic Biologics (NYSEAMERICAN:SYN) Stock

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Receive SYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter.

SYN Stock News Headlines

June 2, 2023 | fool.com
Synthetic Biologics (NYSEMKT: SYN)
June 1, 2023 | forbes.com
Meet The Company Democratizing Access To Human Cells
June 5, 2023 | Edge On The Street (Ad)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
June 1, 2023 | msn.com
UK regulator makes 'final call' to switch off Libor
May 25, 2023 | bizjournals.com
The Petri Dish: FDA delays Sarepta decision; Novartis buys Avrobio drug
May 23, 2023 | finance.yahoo.com
Royal Biologics Announces Licensing and U.S. Commercial Launch of Bio-Reign 3D (TM)
May 11, 2023 | bizjournals.com
2023 Life Sciences Awards: Oerth Bio
May 11, 2023 | markets.businessinsider.com
AbSci (ABSI) Gets a Buy from Berenberg Bank
June 5, 2023 | Edge On The Street (Ad)
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
May 10, 2023 | markets.businessinsider.com
Craig-Hallum Reaffirms Their Hold Rating on Surgalign Holdings (SRGA)
May 10, 2023 | marketwatch.com
Dental Synthetic Bone Material Market Demands, Growth Progress and Value Predication 2023-2029 – Bredent Medical, Cowellmedi, S.B.M. France
May 9, 2023 | marketwatch.com
PUR Biologics Begins Shipment of its Breakthrough Product PURbonedough(TM)
May 9, 2023 | finanznachrichten.de
ORHUB, Inc.: PUR Biologics Begins Shipment of its Breakthrough Product PURbonedough
May 9, 2023 | finance.yahoo.com
Kernal Biologics to Present at Locust Walk RNA Innovation Conference
May 8, 2023 | msn.com
Baird Maintains Twist Bioscience (TWST) Outperform Recommendation
May 5, 2023 | finance.yahoo.com
Global Synthetic Orthobiologics Market to Reach $1.4 Billion by 2030
May 4, 2023 | msn.com
Ask the Expert: Advanced wound care treatment boosts ability to heal
May 4, 2023 | markets.businessinsider.com
H.C. Wainwright Initiates a Buy Rating on AbSci (ABSI)
May 2, 2023 | finance.yahoo.com
Global Hernia Repair Devices Market is estimated to grow at a CAGR of ~5-7% by 2027 - A Revolutionary Solution to Repair Hernias
April 26, 2023 | benzinga.com
Synthetic Biology Market is Expected to Reach $35.7 billion | MarketsandMarkets.
April 24, 2023 | markets.businessinsider.com
Cold Chain Monitoring Market Size Worth USD 12.95 Billion in 2028 – Emergen Research
April 24, 2023 | finance.yahoo.com
Strand Therapeutics Appoints Colleen Wilson as Chief People Officer
April 23, 2023 | msn.com
How Long Does Treatment For Crohn's Disease Take?
April 19, 2023 | markets.businessinsider.com
Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023
April 19, 2023 | finanznachrichten.de
ORHUB, Inc.: US Patent Office Grants PUR Biologics' Breakthrough Patent for Activating Immune Cells
April 19, 2023 | marketwatch.com
Synthetic Adhesion Barriers Market Size, Share, Growth, Trends, Industry Analysis 2023 – 2030
April 19, 2023 | finance.yahoo.com
US Patent Office Grants PUR Biologics' Breakthrough Patent for Activating Immune Cells
See More Headlines

SYN Price History

SYN Company Calendar

Last Earnings
11/02/2021
Today
6/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:SYN
CUSIP
N/A
CIK
894158
Web
www.syntheticbiologics.com
Phone
(301) 417-4364
Fax
301-417-4367
Employees
16
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,270,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.14%
Return on Assets
-22.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.14
Quick Ratio
4.14

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.95 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
15,844,000
Free Float
15,503,000
Market Cap
$16.16 million
Optionable
Not Optionable
Beta
1.38

Key Executives

  • Mr. Steven A. Shallcross CPA (Age 61)
    CEO, CFO, Treasurer, Corp. Sec. & Director
    Comp: $976.91k
  • Dr. Frank Tufaro Ph.D. (Age 67)
    Chief Operating Officer
  • Vincent I. Perrone
    Director of Corp. Communication
  • Dr. Vince Wacher
    Head of Product and Corp. Devel.
  • Dr. Michael Kaleko
    Sr. VP of R&D
  • Ms. Lara M. Guzman
    Sr. Director of Project Operations

Key Competitors

View All Competitors













SYN Stock - Frequently Asked Questions

Should I buy or sell Synthetic Biologics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYN shares.
View SYN analyst ratings or view top-rated stocks.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10.

When did Synthetic Biologics' stock split?

Synthetic Biologics's stock reverse split on the morning of Monday, July 25th 2022. The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), Agenus (AGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), Ampio Pharmaceuticals (AMPE) and Navidea Biopharmaceuticals (NAVB).

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How do I buy shares of Synthetic Biologics?

Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $1.02.

How much money does Synthetic Biologics make?

Synthetic Biologics (NYSEAMERICAN:SYN) has a market capitalization of $16.16 million. The company earns $-14,270,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The official website for the company is www.syntheticbiologics.com. The company can be reached via phone at (301) 417-4364, via email at info@syntheticbiologics.com, or via fax at 301-417-4367.

This page (NYSEAMERICAN:SYN) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -